OMX-0407

News alerts, weekly reports and conference planners

Company:

iOmx Therap

Drug class:

SIK3 inhibitor

Related drugs:

‹

›

7ms

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically (clinicaltrials.gov)

P1/2, N=158, Recruiting, iOmx Therapeutics AG | Phase classification: P1 --> P1/2 | N=30 --> 158 | Trial completion date: May 2025 --> Apr 2026 | Trial primary completion date: Aug 2024 --> Mar 2026

7 months ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date

OMX-0407

almost2years

Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407 (AACR 2023)

By screening sensitive and non-sensitive tumor cell lines and PDX models, we identified a response-prediction biomarker signature. In upcoming clinical studies, this predictive biomarker signature will be evaluated for it’s potential to enrich for patients highly responsive to OMX-0407 therapy.

almost 2 years ago

PD(L)-1 Biomarker • IO biomarker

AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)

OMX-0407

almost3years

OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates tumors in combination with PD-1 inhibition (AACR 2022)

In summary, OMX-0407, a first-in-class oral SIK3 inhibitor, demonstrates potent monotherapy efficacy in a pro-inflammatory tumor setting by reshaping the immune compartment and accelerating tumor cell death. The ability of OMX-0407 to remodel an immunosuppressed TME in a generally cold tumor setting, harbors great clinical potential for OMX-0407 combination therapy with anti-PD-1/PD-L1 immune checkpoint blockade, specifically in patients with high unmet medical need who are resistant to current immune checkpoint inhibitor monotherapy.

almost 3 years ago

Combination therapy

HDAC4 (Histone Deacetylase 4)

OMX-0407